Clinical development risk for IMG-007
The lead asset is still in development, so efficacy or safety setbacks could stop the program.
- Scope
- Atopic dermatitis and broader immunology indications
- Materiality
- high
ImageneBio, Inc.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing immunology and inflammation therapies, with its lead program IMG-007 designed as a non-depleting anti-OX40 monoclonal antibody. The company is focused on advancing IMG-007 for atopic dermatitis and potentially broader autoimmune and inflammatory diseases, while it has also been pursuing strategic alternatives and winding down legacy oncology activities.
−6 006,4 %
−5 668,6 %
−77,1 %
12.49
12.49
| % | |
|---|---|
| Clinical-stage therapeutics | 0% Drug candidates in preclinical and clinical development, centered on IMG-007 and related immunology programs. |
| Licensing revenue | 100% Non-refundable upfront payments and other consideration from IP licensing deals. |
| Collaboration revenue | 0% Revenue from strategic partner arrangements covering research, development, and commercialization rights. |
ImageneBio does not yet sell approved products to end patients; its current counterparties are licensing and...
- Licensing and collaboration partnersprimary
Companies that pay upfront fees, milestones, and royalties for access to ImageneBio's intellectual property and development programs.
- Clinical trial patientsprimary
Patients with atopic dermatitis and other inflammatory diseases enrolled to generate proof-of-concept and safety data for IMG-007.
- Future dermatology and immunology prescribersemerging
Specialist physicians who would prescribe IMG-007 if approved, based on efficacy, safety, and dosing convenience.
- Future payors and health systemsemerging
Insurers and healthcare systems that would reimburse treatment if the product reaches market and demonstrates value.
The company is headquartered in San Diego, California and operates as a U.S.-based development-stage biotech...
- •Headquartered in San Diego, California
- •U.S.-based corporate and R&D operations
- •Relies on third-party manufacturing, including WuXi Biologics
- •Clinical and regulatory activity is global in scope
- •No disclosed country revenue split from product sales
The near-term strategy is centered on advancing IMG-007 in atopic dermatitis and potentially additional immunology and...
01
Advance IMG-007 clinical developmentshort-term
Clinical proof-of-concept data is the main driver of valuation and partnering interest.
02
Complete strategic alternatives / merger processshort-term
The company has been pursuing a transaction to maximize shareholder value and reshape the business.
03
Maintain capital efficiencyshort-term
As a clinical-stage company with no product sales, preserving cash extends runway and reduces dilution risk.
The company faces classic clinical-stage biotech risks: trial failure, regulatory delay, and the need for substantial...
Need for additional capital
The company has no product revenue and expects to fund operations through financing or partnerships.
- Scope
- Dilution, financing availability, runway
- Materiality
- high
Manufacturing concentration
IMG-007 active ingredient and drug product are supplied by a single-source manufacturer.
- Scope
- WuXi Biologics and related supply chain
- Materiality
- high
Strategic alternatives / merger execution
Failure or delay in the proposed merger could materially affect results and stock price.
- Scope
- Inmagene merger process
- Materiality
- high
Competitive pressure
Larger biotech and pharma companies may move faster on similar immunology assets.
- Scope
- Efficacy, safety, dosing convenience, reimbursement
- Materiality
- medium
ASC 606 revenue recognition for licenses and collaborations
Can create quarter-to-quarter revenue volatility
Deferred revenue
Affects reported revenue timing and balance sheet liabilities
R&D expense accruals
Can move operating expense and net loss between periods
Liquidity and going-concern assumptions
Important for runway assessment and disclosure risk
: 28.4.2026